Stocksigma LogoStocksigma Logo

Zydus and MSN Launch First Generic of Adempas in the US

Zydus Lifesciences partnered with MSN Laboratories to launch the first generic version of Adempas (Riociguat Tablets) in the US across all five strengths

Zydus and MSN Launch First Generic of Adempas in the US

Zydus Lifesciences Ltd 路 Press Release 路 06 Oct 2026, 2:14 am

Zydus and MSN Launch First Generic of Adempas in the US Zydus Lifesciences partnered with MSN Laboratories to launch the first generic version of Adempas (Riociguat Tablets) in the US across all five strengths (0.5 mg to 2.5 mg) following USFDA approval. Developed and manufactured by MSN, the drug treats pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The first-to-market generic launch captures significant commercial potential, targeting a therapy where branded Adempas recorded global sales of ~EUR 745mn (~$850mn) in CY25, strengthening Zydus's specialty complex-generics US portfolio.

Original exchange filing (PDF)

More announcements from Zydus Lifesciences Ltd

All Zydus Lifesciences Ltd announcements